Options remain for patients with relapsed/refractory follicular lymphoma, but tazemetostat was the only drug approved specifically for epithelioid sarcoma.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/tazemetostat-pulled-market-over-secondary-cancer-risk-2026a10007bu?src=rss
Author :
Publish date : 2026-03-10 14:16:00
Copyright for syndicated content belongs to the linked Source.